INTESTINE Vol.16 No.2(1)


特集名 大腸SM癌 浸潤距離1,000μmの現状と課題
題名 Overview:大腸SM癌の内視鏡摘除後追加手術の適応基準
発刊年月 2012年 03月
著者 上野 秀樹 防衛医科大学校外科学講座
著者 橋口 陽二郎 防衛医科大学校外科学講座
著者 神藤 英二 防衛医科大学校検査部病理
著者 島崎 英幸 防衛医科大学校外科学講座
著者 長谷 和生 防衛医科大学校外科学講座
【 要旨 】 内視鏡治療が施行された大腸SM癌症例の現状の追加手術の適応基準について,本邦独自の治療指針である,1,000 μmルールと簇出を中心に概説した.より適切な大腸SM癌治療を目指して今後解決すべき課題は,(1) 病理組織学的因子の判定基準の標準化,(2) いわゆるover surgeryの問題の解決のための,高リスク症例の効果的な絞り込み方法,(3) 経過観察症例における再発の実態把握の3点に集約することができる.よくdesignされた多施設研究においてこれらの解決がはかられるべきである.
Theme Invasive colorectal cancer current status and practical issues of depth 1,000μm
Title Treatment strategies for pSM colorectal cancer after endoscopic resection
Author Hideki Ueno Department of Surgery, National Defense Medical College
Author Yojiro Hashiguchi Department of Surgery, National Defense Medical College
Author Eiji Shinto Department of Surgery, National Defense Medical College
Author Hideyuki Shimazaki Department of Laboratorg, National Defense Medical College
Author Kazuo Hase Department of Surgery, National Defense Medical College
[ Summary ] For patients with endoscopically resected T1 colorectal cancer (CRC), additional surgical treatment is recommended when the vertical margin is pathologically positive. If any of the following risk factors is observed in the resected specimens, laparotomy should be considered as an additional treatment option; (1) depth of submucosal invasion ≥ 1,000μm, (2) vascular invasion, (3) unfavorable histology (poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma), (4) grade 2/3 tumor budding.
We can enumerate three points as the issues to be resolved in this field. First, disagreement on histopathologic assessment of risk parameters; second, problems concerning an excessive number of patients undergoing unnecessary laparotomies with the current surgical indications and third, lack of sufficient data concerning the actual status of extramural recurrence in patients having been treated with conservative approachs for endoscopically resected T1 CRC. These issues must be clarified through well-designed multicenter studies which will offer optimal treatment choices for patients with T1 CRC.
戻る